company background image
DHR

DanaherNYSE:DHR Stock Report

Market Cap

US$215.2b

7D

0.5%

1Y

32.5%

Updated

16 Oct, 2021

Data

Company Financials +
DHR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance5/6
Financial Health4/6
Dividends0/6

DHR Overview

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

Danaher Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Danaher
Historical stock prices
Current Share PriceUS$301.38
52 Week HighUS$211.22
52 Week LowUS$333.96
Beta0.72
1 Month Change-6.98%
3 Month Change5.83%
1 Year Change32.50%
3 Year Change200.21%
5 Year Change275.93%
Change since IPO31,010.19%

Recent News & Updates

Oct 01
These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Safely

These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Safely

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Sep 16
If You Like EPS Growth Then Check Out Danaher (NYSE:DHR) Before It's Too Late

If You Like EPS Growth Then Check Out Danaher (NYSE:DHR) Before It's Too Late

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Aug 31
Estimating The Fair Value Of Danaher Corporation (NYSE:DHR)

Estimating The Fair Value Of Danaher Corporation (NYSE:DHR)

Does the August share price for Danaher Corporation ( NYSE:DHR ) reflect what it's really worth? Today, we will...

Aug 06

Danaher's Growth Machine Keeps On Roaring, With No Slowdown In Sight For Bioproduction

The Street expected a strong quarter from Danaher, and they got that and more, with strong growth across the business and significant margin leverage. Bioproduction remains a once-in-a-generation growth opportunity where Danaher has bought its leadership, including the recent deal for Aldevron to build up its plasmid DNA capabilities. PCR-based COVID-19 testing has remained strong for Cepheid, and the company is likewise leveraging pandemic-driven system placements across its full set of test offerings. EAS is recovering nicely, with particularly good growth in Product ID, but this business remains a sale/spin-off candidate. Danaher doesn't really lend itself to sober-minded quantitative valuation approaches, but the growth set-up remains top-notch.

Shareholder Returns

DHRUS Medical EquipmentUS Market
7D0.5%0.6%2.0%
1Y32.5%20.0%27.6%

Return vs Industry: DHR exceeded the US Medical Equipment industry which returned 20% over the past year.

Return vs Market: DHR exceeded the US Market which returned 27.6% over the past year.

Price Volatility

Is DHR's price volatile compared to industry and market?
DHR volatility
DHR Beta0.72
Industry Beta0.88
Market Beta1

Stable Share Price: DHR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: DHR's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196968,000Rainer Blairhttps://www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Danaher Fundamentals Summary

How do Danaher's earnings and revenue compare to its market cap?
DHR fundamental statistics
Market CapUS$215.16b
Earnings (TTM)US$5.36b
Revenue (TTM)US$26.72b

40.1x

P/E Ratio

8.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DHR income statement (TTM)
RevenueUS$26.72b
Cost of RevenueUS$10.60b
Gross ProfitUS$16.12b
ExpensesUS$10.76b
EarningsUS$5.36b

Last Reported Earnings

Jul 02, 2021

Next Earnings Date

Oct 21, 2021

Earnings per share (EPS)7.51
Gross Margin60.33%
Net Profit Margin20.06%
Debt/Equity Ratio47.8%

How did DHR perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

10%

Payout Ratio

Valuation

Is Danaher undervalued compared to its fair value and its price relative to the market?

40.13x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DHR ($301.38) is trading above our estimate of fair value ($258.98)

Significantly Below Fair Value: DHR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DHR is good value based on its PE Ratio (40.1x) compared to the US Medical Equipment industry average (48.4x).

PE vs Market: DHR is poor value based on its PE Ratio (40.1x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: DHR is poor value based on its PEG Ratio (9.1x)


Price to Book Ratio

PB vs Industry: DHR is overvalued based on its PB Ratio (5.4x) compared to the US Medical Equipment industry average (4.3x).


Future Growth

How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

4.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DHR's forecast earnings growth (4.4% per year) is above the savings rate (2%).

Earnings vs Market: DHR's earnings (4.4% per year) are forecast to grow slower than the US market (15.1% per year).

High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.

Revenue vs Market: DHR's revenue (6.2% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: DHR's revenue (6.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (13.3%).


Past Performance

How has Danaher performed over the past 5 years?

15.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DHR has high quality earnings.

Growing Profit Margin: DHR's current net profit margins (20.1%) are higher than last year (15.1%).


Past Earnings Growth Analysis

Earnings Trend: DHR's earnings have grown by 15.5% per year over the past 5 years.

Accelerating Growth: DHR's earnings growth over the past year (88.1%) exceeds its 5-year average (15.5% per year).

Earnings vs Industry: DHR earnings growth over the past year (88.1%) exceeded the Medical Equipment industry 36.1%.


Return on Equity

High ROE: DHR's Return on Equity (12.9%) is considered low.


Financial Health

How is Danaher's financial position?


Financial Position Analysis

Short Term Liabilities: DHR's short term assets ($15.4B) exceed its short term liabilities ($6.8B).

Long Term Liabilities: DHR's short term assets ($15.4B) do not cover its long term liabilities ($28.4B).


Debt to Equity History and Analysis

Debt Level: DHR's debt to equity ratio (47.8%) is considered high.

Reducing Debt: DHR's debt to equity ratio has reduced from 57.9% to 47.8% over the past 5 years.

Debt Coverage: DHR's debt is well covered by operating cash flow (38.9%).

Interest Coverage: DHR's interest payments on its debt are well covered by EBIT (27.5x coverage).


Balance Sheet


Dividend

What is Danaher current dividend yield, its reliability and sustainability?

0.28%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DHR's dividend (0.28%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.29%).

High Dividend: DHR's dividend (0.28%) is low compared to the top 25% of dividend payers in the US market (3.49%).


Stability and Growth of Payments

Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DHR is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Rainer Blair (57 yo)

1.08yrs

Tenure

US$10,396,761

Compensation

Mr. Rainer M. Blair serves as President, Chief Executive Officer and Director at Danaher Corporation since September 1, 2020. Mr. Blair served as an Executive Vice President of Danaher Corporation since Ja...


CEO Compensation Analysis

Compensation vs Market: Rainer's total compensation ($USD10.40M) is about average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Rainer's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: DHR's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: DHR's board of directors are seasoned and experienced ( 11.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DHR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Danaher Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Danaher Corporation
  • Ticker: DHR
  • Exchange: NYSE
  • Founded: 1969
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$215.155b
  • Shares outstanding: 713.90m
  • Website: https://www.danaher.com

Number of Employees


Location

  • Danaher Corporation
  • 2200 Pennsylvania Avenue, NW
  • Suite 800W
  • Washington
  • District Of Columbia
  • 20037-1701
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 22:11
End of Day Share Price2021/10/15 00:00
Earnings2021/07/02
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.